EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer

Kuan-Yu Tseng, Mu-Ying Yang, Wei-Shone Chen, Jeng-Kai Jiang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yi-Wen Yang und 3 weitere

International Journal of Colorectal Disease · 2024

DOI: 10.1007/s00384-024-04767-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2024. Verfasst von Kuan-Yu Tseng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Bevacizumab, Trifluridine, Thymine, Colorectal Neoplasms. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabTrifluridineThymineColorectal NeoplasmsPyrrolidinesProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsNeoplasm MetastasisHumansMaleMiddle AgedFemaleAgedUracilAdultAged, 80 and overDose-Response Relationship, Drug

Stichwörter der Autor:innen

BevacizumabChemotherapyColorectal cancerTAS-102

Substanzen

BevacizumabTrifluridinetrifluridine tipiracil drug combinationThyminePyrrolidinesDrug CombinationsUracil

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Taipei, 11217, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Medical Education, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Colon and Rectum Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Taipei, 11217, Taiwan. hwteng1971@gmail.com.

Zitieren

APA

Tseng, K. Y., Yang, M. Y., Chen, W. S., Jiang, J. K., Wang, H. S., Chang, S. C., Lan, Y. T., Lin, C. C., Lin, H. H., Huang, S. C., Cheng, H. H., Yang, Y. W., Lin, Y. Z., Chang, C. Y., & Teng, H. W. (2024). Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-024-04767-9

Vancouver

Tseng KY, Yang MY, Chen WS, Jiang JK, Wang HS, Chang SC, et al. Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer. International Journal of Colorectal Disease. 2024. doi:10.1007/s00384-024-04767-9

BibTeX
@article{Tseng2024,
  author = {Tseng, Kuan-Yu and Yang, Mu-Ying and Chen, Wei-Shone and Jiang, Jeng-Kai and Wang, Huann-Sheng and Chang, Shih-Ching and Lan, Yuan-Tzu and Lin, Chun-Chi and Lin, Hung-Hsin and Huang, Sheng-Chieh and Cheng, Hou-Hsuan and Yang, Yi-Wen and Lin, Yu-Zu and Chang, Che-Yuan and Teng, Hao-Wei},
  title = {Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer},
  journal = {International Journal of Colorectal Disease},
  year = {2024},
  doi = {10.1007/s00384-024-04767-9}
}
Kostenlos starten →